08 January 2013

Successful cooperation between research institutes uncovers promising candidates for cancer therapy

Anti-psychotics in cancer therapy

Researchers from the Helmholtz Zentrum München, the FMP in Berlin and two other collaboratoring institutes found anti-cancer effects of known anti-psychotics.

A team of researchers headed by Daniel Krappmann from the Helmholtz Zentrum München published a new and unexpected effect of anti-psychotic drugs on a severe form of diffuse large B-cell lymphoma printed in the December issue of the renowned journal “Cancer Cell”. The discovery of this promising novel anti-cancer therapy was enabled through a close collaboration between members of different research institutes.

The effect on lymphoma cells of two established drugs, Mepazine and Thioridazine, was found during the screen of 18,000 compounds form the ChemBioNet collection at the Screening Unit of the Leibniz Institute of Molecular Pharmacology (FMP). Both compounds were able to inhibit the protease MALT1 resulting in the death of lymphoma cells. The screening results could be confirmed in preclinical studies conducted in close collaboration of the Helmholtz Zentrum München, the Charité in Berlin and the Philipps-Universität Marburg.

 

Original publikation:

Nagel D. (2012), Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL. Cancer Cell, Volume 22, Issue 6, 11 December 2012. Pages 825–837

back to Overview